{"article": [{"url": "https://www.marketwatch.com/story/astrazenecas-covid-19-vaccine-trial-in-the-us-remains-halted-report-2020-09-14", "published": 1600099940.0, "headline": "AstraZeneca's COVID-19 vaccine trial in the U.S. remains halted: report", "body": "U.S. trials of AstraZeneca Plc.'s AZN, +1.16% and Oxford University COVID-19 vaccine candidate will be on hold until at least midweek, pending a Federal Drug Administration investigation into the side effect that caused trials to be halted earlier this month, Reuters reported Monday, citing sources familiar with the matter. AstraZeneca on Saturday said U.K. clinical trials had resumed. The vaccine candidate's trials were halted after a reported side effect in a U.K. patient. Reuters said new-patient enrollment and other steps in the U.S. trial are being rescheduled until at least midweek and it was not clear how long federal regulators would take to complete its investigation. American depositary shares of AstraZeneca ended 0.5% higher on Monday, and have gained 8% this year, compared with gains around 5% for the S&P 500 index. SPX, +0.87%"}]}